Business Context and Reporting Period
Company: American BriVision (Holding) Corporation (ABVC Biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date: May 23, 2019
Event: Announcement of Phase II clinical study results for ABV-1504 (active ingredient PDC-1421) targeting Major Depressive Disorder (MDD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial outcomes.
Material Changes and Clinical Results
The Company reported positive results from a randomized, double-blind, placebo-controlled, multi-center Phase II trial involving 60 adult patients with moderate to severe MDD.
- Primary Endpoint: The high dose of PDC-1421 (2 x 380 mg) met the pre-specified primary endpoint.
- Efficacy: High dose demonstrated a 13.2-point reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score (Intention-To-Treat analysis) compared to a 9.2-point reduction in the placebo group over a 6-week period.
- Safety: Both low dose (380 mg) and high dose regimens were found safe and well tolerated with no serious adverse events reported.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, forward-looking projections, or a detailed discussion of risks and contingencies beyond the standard context of clinical development. The primary outlook is the successful demonstration of efficacy and safety for the MDD treatment candidate.
Investor Verification Checklist
- Verify the statistical significance of the 13.2-point vs. 9.2-point MADRS reduction difference.
- Confirm the regulatory pathway and timeline for potential Phase III trials following these results.
- Review the Company's current cash position and capital requirements to fund future development stages, as this 8-K does not disclose financial status.
- Check for any pending regulatory filings or updates regarding the specific dosing regimen (380 mg vs. 760 mg).